Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan

What Was Tested

The paper reports a study of Somatostatin and Lanreotide, published as a clinical trial, phase iii.

Analysis was performed on data from patients receiving preoperative treatment (n = 6) up to 24 weeks and from those receiving primary or postoperative treatment (n = 7) up to 52 weeks.

FT4 at final assessment was within reference ranges in 10/13 patients.

Who Took Part

According to the abstract, 13 patients were involved.

PubMed tags the participants as both men and women.

How the Study Was Run

The design is described as multicenter.

Running at several centres spread the Somatostatin study over different clinics and patient groups.

A time span of 24 weeks appears in the methods.

What Was Measured

Analysis was performed on data from patients receiving preoperative treatment (n = 6) up to 24 weeks and from those receiving primary or postoperative treatment (n = 7) up to 52 weeks.

FT4 at final assessment was within reference ranges in 10/13 patients.

The subject headings attached to it are Adenoma, Antineoplastic Agents, Japan, Neoadjuvant Therapy, Peptides, Cyclic, Pituitary Neoplasms and Preoperative Care.

Author keywords: Clinical study, Lanreotide, Preoperative treatment, Somatostatin analog and Thyroid-stimulating hormone-secreting pituitary adenoma.

What This Means in Plain Language

The paper is a multicenter study of Somatostatin and Lanreotide in 13 patients over 24 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2021 (Endocrine journal), a journal based in Japan.

More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.